<!DOCTYPE html>
<html lang="en">
  <head>
    <title>S24LidforssCRISPR - Streamline</title>
    <meta
      name="description"
      content="Streamline - The Rivers School's STEM Magazine &amp; Outreach Club"
    />
    <meta property="og:title" content="S24LidforssCRISPR - Streamline" />
    <meta
      property="og:description"
      content="Streamline - The Rivers School's STEM Magazine &amp; Outreach Club"
    />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta charset="utf-8" />
    <meta property="twitter:card" content="summary_large_image" />

    <style data-tag="reset-style-sheet">
      html {  line-height: 1.15;}body {  margin: 0;}* {  box-sizing: border-box;  border-width: 0;  border-style: solid;}p,li,ul,pre,div,h1,h2,h3,h4,h5,h6,figure,blockquote,figcaption {  margin: 0;  padding: 0;}button {  background-color: transparent;}button,input,optgroup,select,textarea {  font-family: inherit;  font-size: 100%;  line-height: 1.15;  margin: 0;}button,select {  text-transform: none;}button,[type="button"],[type="reset"],[type="submit"] {  -webkit-appearance: button;}button::-moz-focus-inner,[type="button"]::-moz-focus-inner,[type="reset"]::-moz-focus-inner,[type="submit"]::-moz-focus-inner {  border-style: none;  padding: 0;}button:-moz-focus,[type="button"]:-moz-focus,[type="reset"]:-moz-focus,[type="submit"]:-moz-focus {  outline: 1px dotted ButtonText;}a {  color: inherit;  text-decoration: inherit;}input {  padding: 2px 4px;}img {  display: block;}html { scroll-behavior: smooth  }
    </style>
    <style data-tag="default-style-sheet">
      html {
        font-family: Inter;
        font-size: 16px;
      }

      body {
        font-weight: 400;
        font-style:normal;
        text-decoration: none;
        text-transform: none;
        letter-spacing: normal;
        line-height: 1.15;
        color: var(--dl-color-gray-black);
        background-color: var(--dl-color-gray-white);

        null
      }
    </style>
    <link
      rel="stylesheet"
      href="https://unpkg.com/animate.css@4.1.1/animate.css"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Poppins:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=PT+Sans:ital,wght@0,400;0,700;1,400;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Oxygen:wght@300;400;700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Work+Sans:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Poppins:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,500;0,600;0,700;0,800;1,300;1,400;1,500;1,600;1,700;1,800&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Poppins:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Plus+Jakarta+Sans:ital,wght@0,200;0,300;0,400;0,500;0,600;0,700;0,800;1,200;1,300;1,400;1,500;1,600;1,700;1,800&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Plus+Jakarta+Sans:ital,wght@0,200;0,300;0,400;0,500;0,600;0,700;0,800;1,200;1,300;1,400;1,500;1,600;1,700;1,800&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Spectral:ital,wght@0,200;0,300;0,400;0,500;0,600;0,700;0,800;1,200;1,300;1,400;1,500;1,600;1,700;1,800&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Roboto:ital,wght@0,100;0,300;0,400;0,500;0,700;0,900;1,100;1,300;1,400;1,500;1,700;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Fira+Sans:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Exo+2:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Poppins:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Source+Sans+3:ital,wght@0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Poppins:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Noto+Sans:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Plus+Jakarta+Sans:ital,wght@0,200;0,300;0,400;0,500;0,600;0,700;0,800;1,200;1,300;1,400;1,500;1,600;1,700;1,800&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Poppins:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Inter:wght@100;200;300;400;500;600;700;800;900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Poppins:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Poppins:ital,wght@0,100;0,200;0,300;0,400;0,500;0,600;0,700;0,800;0,900;1,100;1,200;1,300;1,400;1,500;1,600;1,700;1,800;1,900&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Lora:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500;1,600;1,700&amp;display=swap"
      data-tag="font"
    />
    <link
      rel="stylesheet"
      href="https://unpkg.com/@teleporthq/teleport-custom-scripts/dist/style.css"
    />
  </head>
  <body>
    <link rel="stylesheet" href="./style.css" />
    <div>
      <link href="./s24-lidforss-crispr.css" rel="stylesheet" />

      <div class="s24-lidforss-crispr-container">
        <div class="s24-lidforss-crispr-content">
          <div class="s24-lidforss-crispr-nav-bar">
            <img
              alt="Rectangle1I145"
              src="public/external/rectangle1i145-k1uq-200h.png"
              class="s24-lidforss-crispr-rectangle1"
            />
            <div class="s24-lidforss-crispr-group1">
              <img
                alt="Ellipse1I145"
                src="public/Streamline/logo_1-600w.png"
                class="s24-lidforss-crispr-ellipse1"
              />
              <span class="s24-lidforss-crispr-text">
                The Rivers Streamline
              </span>
            </div>
            <div class="s24-lidforss-crispr-group3">
              <a href="index.html" class="s24-lidforss-crispr-text001">Home</a>
              <span class="s24-lidforss-crispr-text002">About</span>
              <a
                href="https://www.instagram.com/rivers.streamline/"
                target="_blank"
                rel="noreferrer noopener"
                class="s24-lidforss-crispr-text003"
              >
                <span>Instagram</span>
                <br />
                <br />
              </a>
            </div>
          </div>
          <div class="s24-lidforss-crispr-content1">
            <div class="s24-lidforss-crispr-main-content">
              <div class="s24-lidforss-crispr-content2">
                <div class="s24-lidforss-crispr-oarticle">
                  <div class="s24-lidforss-crispr-blog-info">
                    <div class="s24-lidforss-crispr-heading">
                      <span class="s24-lidforss-crispr-text007">
                        An Exploration of CRISPR in Sickle Cell Disease
                        Treatment
                      </span>
                    </div>
                    <div class="s24-lidforss-crispr-short-info">
                      <div class="s24-lidforss-crispr-aauthor">
                        <img
                          alt="ImageI2101"
                          src="public/external/imagei2101-pano-200h.png"
                          class="s24-lidforss-crispr-image"
                        />
                        <span class="s24-lidforss-crispr-text008">
                          Nicole Lidforss '25
                        </span>
                      </div>
                      <span class="s24-lidforss-crispr-text009">
                        Spring 2024
                      </span>
                    </div>
                  </div>
                  <img
                    alt="Image2101"
                    src="https://www.iberdrola.com/documents/20125/1527375/CRISPR-726x484.jpg/46cb36ee-b5e4-9ef6-47b1-2094abac7909?t=1642007315492"
                    loading="lazy"
                    class="s24-lidforss-crispr-image1"
                  />
                  <div class="s24-lidforss-crispr-para"></div>
                  <span class="s24-lidforss-crispr-text010">Introduction</span>
                  <div class="s24-lidforss-crispr-para1">
                    <span class="s24-lidforss-crispr-text011">
                      <span class="AMainArticleText">
                        Sickle cell disease is a group of inherited blood
                        disorders affecting approximately 100,000 people in the
                        U.S. It is most common in African Americans, but also
                        disproportionately affects Hispanic Americans. The
                        primary problem in sickle cell disease is a mutation in
                        hemoglobin, a protein in red blood cells that transports
                        oxygen to the body’s tissues. This mutation causes red
                        blood cells to appear in a “sickle” shape. These mutated
                        red blood cells restrict blood flow in vessels and limit
                        oxygen delivery to the body’s tissues, leading to severe
                        pain and organ damage called vaso-occlusive events
                        (VOEs) or vaso-occlusive crises (VOCs). The recurrence
                        of these crises can lead to life-threatening
                        disabilities and/or early death.
                      </span>
                      <br class="AMainArticleText" />
                      <span class="AMainArticleText"></span>
                      <br class="s24-lidforss-crispr-text015" />
                      <span class="AMainArticleText">
                        A relatively new technology that research scientists use
                        to selectively modify the DNA of living organisms,
                        CRISPR, has just been implemented into sickle cell
                        treatment. CRISPR was adapted for use in the laboratory
                        from naturally occurring genome editing systems found in
                        bacteria. On December 8, 2023, the first ever CRISPR
                        gene therapy treatments were approved by the FDA for use
                        in patients over the age of 12. There are so many
                        potential benefits such as reducing the need for
                        frequent and time consuming hospital visits, reducing
                        pain, and improving overall quality of life. Nicole
                        Verdun, M.D., director of the Office of Therapeutic
                        Products within the FDA’s Center for Biologics
                        Evaluation and Research writes, “Gene therapy holds the
                        promise of delivering more targeted and effective
                        treatments, especially for individuals with rare
                        diseases where the current treatment options are
                        limited”. With that being said, as the use of Cas9 in
                        treatment is so new, there is so much we do not know
                        about it. It is extremely important to take the many
                        potential risks into account. Accordingly, this
                        controversial topic leads to the question, is it ethical
                        to use CRISPR as a treatment for sickle cell disease,
                        and what exactly is at stake?
                      </span>
                      <br class="AMainArticleText" />
                    </span>
                  </div>
                  <img
                    alt="Image2101"
                    src="https://www.froedtert.com/sites/default/files/upload/images/services/sickle-cell/sickle-cell-blood-cells.jpg"
                    loading="lazy"
                    class="s24-lidforss-crispr-image2"
                  />
                  <span class="s24-lidforss-crispr-text018">
                    <span>Sickle Cell Treatment Today</span>
                    <br />
                  </span>
                  <span class="s24-lidforss-crispr-text021">
                    <span class="AMainArticleText">
                      The most common treatment of sickle cell today is blood
                      transfusions. When anemia, a low blood cell count, is
                      severe, conditions including splenic sequestration, acute
                      chest syndrome, and aplastic crisis are life threatening
                      if not treated with blood transfusions. These transfusions
                      increase the number of normal red blood cells in the body,
                      increasing the supply of oxygen to the body.
                    </span>
                    <br class="s24-lidforss-crispr-text023" />
                    <br class="AMainArticleText" />
                    <span class="AMainArticleText">
                      An argument for CRISPR in sickle cell disease treatment
                      are the benefits of eliminating downsides of today’s most
                      common treatments, such as blood transfusions. While blood
                      transfusions can help reduce the frequency and severity of
                      sickle cell-related complications, they do not completely
                      eliminate the symptoms. Alloimmunization, the development
                      of antibodies against transfused blood, transmission of
                      infectious diseases such as hepatitis or HIV, and allergic
                      reactions can occur as a result of repeated transfusions.
                      Also, finding compatible blood for transfusions can be
                      challenging and may require extensive screening and
                      matching procedures.
                    </span>
                    <br class="AMainArticleText" />
                  </span>
                  <span class="s24-lidforss-crispr-text027">
                    Current CRISPR Therapies
                  </span>
                  <span class="s24-lidforss-crispr-text028 AMainArticleText">
                    <span class="AMainArticleText">
                      At this point, two gene therapies involving the use of
                      Cas9 for treating sickle cell disease have been approved
                      by the FDA for patients 12 years of age and older with
                      recurring vaso-occlusive crises, Casgevy (also called
                      exa-cel) and Lyfgenia. Casgevy is a cell-based gene
                      therapy created by the companies Vertex and CRISPR
                      Therapeutics. The treatment involves mobilizing a
                      patient's own bone marrow stem cells from the blood. The
                      stem cells are edited at a specific region of the BCL11A
                      gene which prevents the production of fetal hemoglobin
                      (HbF), a type of hemoglobin that facilitates oxygen
                      delivery. In patients with SCD, increased levels of HbF
                      prevent the sickling of red blood cells. The reduction of
                      BCL11A gene transcription in the patient’s RNA leads to an
                      increase of HbF production, thus providing functioning
                      hemoglobin. The modified blood stem cells are transplanted
                      back into the patient where they attach and multiply
                      within the bone marrow. The second approved treatment,
                      Lyfgenia, is similar to Casgevy, but is not as common. The
                      patient’s blood stem cells are genetically altered to
                      produce HbAT87Q, a gene-therapy extracted hemoglobin that
                      works similarly to hemoglobin A, which is the normal adult
                      hemoglobin. Red blood cells containing HbAT87Q have a
                      lower risk of sickling and blocking blood flow. These
                      modified stem cells are then transplanted into the
                      patient. “These approvals represent an important medical
                      advance with the use of innovative cell-based gene
                      therapies to target potentially devastating diseases and
                      improve public health,” writes Peter Marks, M.D., Ph.D.,
                      director of the FDA’s Center for Biologics Evaluation and
                      Research.
                    </span>
                    <br class="AMainArticleText" />
                  </span>
                  <img
                    alt="Image2101"
                    src="https://pwonlyias.com/wp-content/uploads/2023/11/Untitled-560-scaled.webp"
                    class="s24-lidforss-crispr-image3"
                  />
                  <span class="s24-lidforss-crispr-text031">
                    <span>Ethical considerations: Justice</span>
                    <br />
                  </span>
                  <div class="s24-lidforss-crispr-para2">
                    <span class="s24-lidforss-crispr-text034 AMainArticleText">
                      <span class="AMainArticleText">
                        The medical field has a long history of racism, and it
                        is important to consider that the majority of the people
                        affected by this disease and would be receiving CRISPR
                        treatment are black. Throughout the Jim Crow era in the
                        United States, segregation extended to healthcare
                        facilities, with black individuals often relegated to
                        substandard and underfunded hospitals and clinics. They
                        received inferior medical care compared to their white
                        counterparts, leading to stark disparities in health
                        outcomes. While overt forms of medical racism have
                        diminished over time, systemic biases and disparities
                        persist in healthcare systems worldwide. The use of
                        CRISPR in sickle cell disease treatment has the
                        possibility of doing immense good for a group that has
                        historically been neglected in the medical world.
                        However, if these gene therapies were to not go as
                        planned, this mistreated minority will be further
                        punished by the medical industry. Keeping these facts in
                        mind while considering the expansion of CRISPR SCD
                        treatment is crucial to the making of related major
                        decisions and guidelines.
                      </span>
                      <br class="AMainArticleText" />
                    </span>
                    <span class="s24-lidforss-crispr-text037">
                      <span>Ethical considerations: Accessibility</span>
                      <br />
                    </span>
                    <span class="s24-lidforss-crispr-text040">
                      <span class="AMainArticleText">
                        Cost is a large topic of discussion as various sickle
                        cell expenses accumulate to be devastatingly costly.
                        SCD-related lifetime medical costs (blood transfusions
                        and included inpatient care) were estimated at almost
                        1.7 million dollars. While the majority of this cost is
                        covered by insurance, the disease and its implications
                        are very time consuming. Most people have to come in to
                        receive a blood transfusion once or even twice a month.
                        These hospital visits are inconvenient and often get in
                        the way of one’s day.
                      </span>
                      <br class="s24-lidforss-crispr-text042" />
                      <br class="AMainArticleText" />
                      <span class="AMainArticleText">
                        With that being said, one of the most critical issues
                        about these novel CRISPR treatments is their current
                        cost. Like most gene editing therapies, exa-cel and
                        lovo-cell are likely to be very expensive. Estimates
                        suggest that the price for each could be as much as $2
                        million per patient. Arafa Salim, who has used her own
                        experience with sickle cell to build Tanzania’s first
                        patient advocacy organization claimed, “A new therapy
                        can be extremely effective, even a cure for sickle cell,
                        but if it’s not made accessible to the average patient,
                        it won’t be used.” Additionally, insurance companies are
                        often motivated by a utilitarian ethic of providing the
                        most good to the most people and could potentially deny
                        especially expensive treatments that are deemed
                        “experimental” and “not medically necessary,” meaning
                        patients will have to pay out of pocket for these
                        treatments, which is just not possible for most. As more
                        CRISPR treatments and genetic modification are released,
                        it is conceivable that only the wealthy will have access
                        to this technology as far as we know. However, a
                        one-time gene editing treatment has the potential to
                        alleviate some of the long-term costs, including the
                        cost of treatment, travel, and lost time or productivity
                        for treatment. Furthermore if companies eventually get
                        the cost of genetic therapies down and gene therapies
                        become “standard of care”, perhaps health insurance will
                        begin to cover CRISPR treatments. However, as of today,
                        these therapies will not be covered by insurance for a
                        long time as companies tend to wait as long as possible
                        before covering a treatment, especially the more
                        expensive ones.
                      </span>
                      <br class="AMainArticleText" />
                    </span>
                  </div>
                  <div class="s24-lidforss-crispr-quote">
                    <span
                      class="s24-lidforss-crispr-text046 ArticlequoteRegular"
                    >
                      <span>
                        "As a society, we must determine if the beneficence
                        outweighs the maleficence this new technology may cause.
                        This development uncovers an entirely new chapter of the
                        future of the medical field."
                      </span>
                      <br class="ArticlequoteRegular" />
                    </span>
                  </div>
                  <span class="s24-lidforss-crispr-text049">
                    <span>Conclusions and Recommendations</span>
                    <br />
                  </span>
                  <span class="s24-lidforss-crispr-text052">
                    <span class="AMainArticleText">
                      Given the previous discussion, the question of whether it
                      is ethical to use CRISPR in sickle cell treatments is
                      vastly controversial, and has seemingly unlimited
                      arguments for and against it. As a society, we must
                      determine if the beneficence outweighs the maleficence
                      this new technology may cause. This development uncovers
                      an entirely new chapter of the future of the medical
                      field.
                    </span>
                    <br class="s24-lidforss-crispr-text054" />
                    <br class="AMainArticleText" />
                    <span class="AMainArticleText">
                      In order for the use of gene editing therapies to be
                      ethical, there must be specific, strict policies from the
                      federal government. First off, the government should
                      prioritize equity considerations in determining access,
                      specifically cost-wise. Individuals who cannot pay for,
                      whose insurance does not cover these treatments, or do not
                      live near a facility that provides CRISPR therapies should
                      be accordingly supported. Patients must also be thoroughly
                      informed of potential side effects that may occur from
                      treatment. Informed consent for individuals who are not
                      literate, do not speak the language spoken in the country
                      they are in, and are differently abled should be
                      adequately adapted to provide clear and fair communication
                      of the potential risks and benefits of such treatments.
                      And finally, there must be extensive and strict
                      regulations to CRISPR technology in medical facilities to
                      ensure no person or group handling these treatments goes
                      beyond the societally decided limits. Finally, as a
                      society we must come together and have intensive ethical
                      discussions before further advancing CRISPR in medicine.
                      Under these circumstances, CRISPR in medicine should and
                      will be used to treat genetic diseases such as sickle cell
                      disease to advance the future of humanity.
                    </span>
                    <br class="s24-lidforss-crispr-text057" />
                    <br class="AMainArticleText" />
                  </span>
                </div>
                <div class="s24-lidforss-crispr-oconclusion">
                  <div class="s24-lidforss-crispr-para3">
                    <span class="s24-lidforss-crispr-text059">Sources:</span>
                    <span class="s24-lidforss-crispr-link">
                      <span>
                        Office of the Commissioner. “FDA Approves First Gene
                        Therapies to Treat Patients with Sickle Cell Disease.”
                        FDA, 8 Dec. 2023,
                        www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease#:~:text=Casgevy%2C%20a%20cell%2Dbased%20gene.
                        Accessed 6 Jan. 2024.
                      </span>
                      <br />
                      <br />
                      <span>
                        Smith, Mike. 2023. “CRISPR.” Genome.gov. 2023.
                        https://www.genome.gov/genetics-glossary/CRISPR.
                      </span>
                      <br />
                      <br />
                      <span>
                        Peebles, Angelica. 2023. “U.S. Approves First
                        Gene-Editing Treatment, Casgevy, for Sickle Cell
                        Disease.” CNBC. December 8, 2023.
                        https://www.cnbc.com/2023/12/08/casgevy-first-crispr-gene-editing-treatment-approved-in-us.html.
                      </span>
                      <br />
                      <br />
                      <span>
                        Uddin, Fathema, et al. “CRISPR Gene Therapy:
                        Applications, Limitations, and Implications for the
                        Future.” Frontiers in Oncology, vol. 10, no. 1387, 7
                        Aug. 2020, https://doi.org/10.3389/fonc.2020.01387.
                      </span>
                      <br />
                      <br />
                      <span>
                        Neidler, Sarah. 2020. “Blood Transfusion - Sickle Cell
                        Disease News.” Sickle Cell Disease News. March 5, 2020.
                        https://sicklecellanemianews.com/blood-transfusion/#:~:text=Simple%20transfusions%20are%20typically%20given
                      </span>
                      <br />
                      <br />
                      <span>
                        Pagliarulo, Ned, and Shaun Lucas. “What If a CRISPR Cure
                        Isn’t Such an Easy Choice?” BioPharma Dive, 8 Nov. 2023,
                        www.biopharmadive.com/news/sickle-cell-crispr-gene-editing-vertex-exa-cel-barriers/698121/.
                        Accessed 13 Jan. 2024.
                      </span>
                      <br />
                      <br />
                      <span>
                        Reardon, Sara. 2023. “FDA Approves First CRISPR Gene
                        Editing Treatment for Sickle Cell Disease.” Scientific
                        American. December 28, 2023.
                        https://www.scientificamerican.com/article/fda-approves-first-crispr-gene-editing-treatment-for-sickle-cell-disease/#:~:text=Like%20most%20gene%20editing%20therapies.
                      </span>
                      <br />
                      <span></span>
                      <br />
                    </span>
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div id="footer" class="s24-lidforss-crispr-footer">
            <div class="s24-lidforss-crispr-contents">
              <span class="s24-lidforss-crispr-text082">
                <span class="s24-lidforss-crispr-text083">Contact Us</span>
                <br />
              </span>
              <span class="s24-lidforss-crispr-text085">
                <br />
                <span>Co-founders:</span>
                <br />
                <span>Chelsea Yan: c.yan@rivers.org</span>
                <br />
                <span>Joyce Do:&nbsp;joyce.do@rivers.org</span>
                <br />
                <br />
                <span>Faculty Advisor:</span>
                <br />
                <span>Stewart Pierson: s.pierson@rivers.org</span>
              </span>
            </div>
            <div class="s24-lidforss-crispr-contents1">
              <span class="s24-lidforss-crispr-text097">
                <span class="s24-lidforss-crispr-text098">About</span>
                <br />
              </span>
              <span class="s24-lidforss-crispr-text100">
                <br />
                <span>
                  This website showcases the original written work of members of
                  Streamline. Streamline is a&nbsp;
                </span>
                <br />
                <span>student-run magazine and club at The Rivers School.</span>
                <br />
              </span>
            </div>
            <img
              alt="image"
              src="public/Streamline/logo_1-600w.png"
              class="s24-lidforss-crispr-image4"
            />
          </div>
        </div>
      </div>
    </div>
  </body>
</html>
